Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Recombinant Porcine FVIII in Acquired Hemophilia: Decreased Product Usage When Used Upfront, Non-Utility of Baseline Porcine Bethesda Titer, and Confirmation of Dosing Algorithm

Patrick Ellsworth, MD, Sheh-Li Chen, PharmD, Nigel S. Key, MBChB, FRCP, Raj S. Kasthuri, MD, Micah J. Mooberry, MD, Alice D. Ma, MD

Blood (2018) 132 (Supplement 1): 2474.

https://doi.org/10.1182/blood-2018-99-118839

Published: 2018

Journal Articles

Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy

Patrick Ellsworth, MD, Sheh-Li Chen, PharmD, Yasmina L. Abajas, MD, Stephan Moll, MD, Nigel S. Key, MBChB, FRCP, Alice D. Ma, MD

Blood (2018) 132 (Supplement 1): 1202.

https://doi.org/10.1182/blood-2018-99-119196

Published: 2018

Journal Articles

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Marilyn J. Manco-Johnson, MD, Alice D. Ma, MD, Robert Klamroth, Werner Engl, Lorena Griparic, PhD, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2300.

https://doi.org/10.1182/blood.V126.23.2300.2300

Published: 2015

Journal Articles

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Alice D. Ma, MD, Robert Klamroth, Marilyn J. Manco-Johnson, MD, Werner Engl, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 1105.

https://doi.org/10.1182/blood.V126.23.1105.1105

Published: 2015

Journal Articles

Von Willebrand Factor for Menorrhagia: A Survey and Literature Review

Nicoletta Machin, MD, Margaret V. Ragni, MD MPH, Lynn M. Malec, MD, Donald Brambilla, PhD, Thomas Coyle, MD, Joanna A. Davis, MD, Annette Drygalski, Andra H James, MD MPH, Shawn M Jobe, MD PhD, Barbara A. Konkle, MD, Peter Kouides, MD, Philip Kuriakose, MD, Alice D. Ma, MD, Elaine M. Majerus, MD PhD, Danielle Nance, MD, Anne T. Neff, MD, Claire S. Philipp, MD, Tzu-Fei Wang, MD, Hassan M. Yaish, MD

Blood (2015) 126 (23): 4694.

https://doi.org/10.1182/blood.V126.23.4694.4694

Published: 2015

Journal Articles

Importance of Pharmacokinetic Studies in the Management of Acquired Factor X Deficiency

Ming Yeong Lim, MBBChir, Timothy A. McCarthy, MD, Sheh-Li Chen, Pharm D, Alice D Ma, MD

Blood (2014) 124 (21): 5059.

https://doi.org/10.1182/blood.V124.21.5059.5059

Published: 2014

Journal Articles

Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study

Alice D. Ma, MD, Craig M. Kessler, MD, Hamid A B Al-Mondhiry, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 4624.

https://doi.org/10.1182/blood.V120.21.4624.4624

Published: 2012

Journal Articles

The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US

Craig M. Kessler, MD, Alice D. Ma, MD, Hamid A B Al-Mondhiry, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 4625.

https://doi.org/10.1182/blood.V120.21.4625.4625

Published: 2012

Journal Articles

US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry

Hamid A B Al-Mondhiry, MD, Alice D. Ma, MD, Craig M. Kessler, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 3372.

https://doi.org/10.1182/blood.V120.21.3372.3372

Published: 2012

Journal Articles

Hyperferritinemia and Hemophagocytic Lymphohistiocytosis. Single Institution Experience in Adult and Pediatric Patients.

Alice D. Ma, MD, Yuri D. Fedoriw, MD, Philip Roehrs, MD

Blood (2012) 120 (21): 2135.

https://doi.org/10.1182/blood.V120.21.2135.2135

Published: 2012

Journal Articles

Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,

Alice D. Ma, MD, Craig M. Kessler, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3374.

https://doi.org/10.1182/blood.V118.21.3374.3374

Published: 2011

Journal Articles

Single Center Experience with Rituximab as First Line Immunosuppression Regimen for Acquired Hemophilia

Jeremiah Boles, MD, Nigel S. Key, MBChB, Raj S. Kasthuri, MD, MBBS, Alice D. Ma, MD

Blood (2010) 116 (21): 1419.

https://doi.org/10.1182/blood.V116.21.1419.1419

Published: 2010

Journal Articles

Treatment of Acute Bleeds in Acquired Hemophilia: An Updated Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry.

Suman L. Sood, MD, Barbara A. Konkle, Craig M. Kessler, MD, Alice D. Ma, MD, David L. Cooper, MD, MBA, The HTRS Registry Investigators

Blood (2009) 114 (22): 3499.

https://doi.org/10.1182/blood.V114.22.3499.3499

Published: 2009

NARROW

Recombinant Porcine FVIII in Acquired Hemophilia: Decreased Product Usage When Used Upfront, Non-Utility of Baseline Porcine Bethesda Titer, and Confirmation of Dosing Algorithm

Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Von Willebrand Factor for Menorrhagia: A Survey and Literature Review

Importance of Pharmacokinetic Studies in the Management of Acquired Factor X Deficiency

Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study

The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US

US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry

Hyperferritinemia and Hemophagocytic Lymphohistiocytosis. Single Institution Experience in Adult and Pediatric Patients.

Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,

Single Center Experience with Rituximab as First Line Immunosuppression Regimen for Acquired Hemophilia

Treatment of Acute Bleeds in Acquired Hemophilia: An Updated Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only